Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 August 2021 | Story André Damons | Photo Charl Devenish
Ebeth Grobbelaar is a Scientific Manager in the South African Doping Control Laboratory (SADoCoL) who is responsible for the review and approval of results at SADoCoL, to ensure compliance with the technical requirements of the World Anti-Doping Agency (WADA).

For Ebeth Grobbelaar, Scientific Manager in the South African Doping Control Laboratory (SADoCoL) – which is housed by the University of the Free State (UFS) – her work at the laboratory is profound, as fairness on and off the playing field is vital to her.

“Creating a fair playing field for athletes to compete carries a heavy responsibility, as an anti-doping violation impacts the athlete’s career,” says Grobbelaar, who is responsible for the review and approval of results at SADoCoL to ensure compliance with the technical requirements of the World Anti-Doping Agency (WADA).

Women are the cogs in the wheel

According to her, anabolic steroids, the multiple analytical disciplines, and rapidly changing technical requirements from WADA have attracted her to the sciences of anti-doping. Sixty percent of her colleagues at SADoCoL are women.  “They are the cogs in the wheel, ensuring the laboratory's smooth operation, taking daily challenges in their stride, and excelling in what they do as analysts and administrative staff,” says Grobbelaar.

Grobbelaar says there are many options in the anti-doping field for women inside and outside of the laboratory. Some of the most influential people in the anti-doping community are women – in their roles as laboratory directors, leading researchers, directors of athlete passport management units for international sports federations, or national anti-doping agencies in various capacities.

With all the responsibilities, come challenges and pressure – especially in a year when the Olympic Games take place. 

Women should learn how to say ‘no’ 

“An Olympic year always has additional stress due to the large number of samples before the games. This year, the pressure is more, with not all accredited laboratories operational, as well as disrupted testing schedules due to COVID-19.  Enabling athletes to compete in fairness on the world stage is a responsibility and a privilege.”

“My faith is my anchor.  As far as possible, I try to leave my work behind when I leave the laboratory, and concentrate on enjoyable things such as gardening, my dog, reading, and walking with my dog. On challenging days, something sweet also helps,” explains Grobbelaar the pressure and how she copes with it. 

This Women’s Month, Grobbelaar says, women should learn how to say ‘no’ to create time for rest and play. Says Grobbelaar: “For many women, ‘doing your best’ or saying yes means working yourself to the point of a mental and physical breakdown. Having the courage to say no, loving oneself through rest and play, replenishing our spirits, and realising that we are unique and precious in God’s eyes, is a challenge that many women face.” 

“Rest and play can take different forms, such as having coffee with a friend or being creative.  The important thing is that your rest or play activity brings joy to your soul and energises you. Ask your friends to support and assist you,” she concludes. 

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept